They found that motolimod treatment reduced MDSCs levels in healthy donors and cancer patients, and concluded that TLR8 agonists could be deployed in conjunction with cancer immunotherapeutic approaches in order to enhance the anti-tumor effects of the adaptive immune response [69]. Here, TLR8 is linked to cancer.